Mode
Text Size
Log in / Sign up

Solid organ transplant recipients face higher cancer-related mortality with SMR 2.21 across multiple organsOrgan transplant recipients face higher risk of certain cancers

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note higher cancer-related mortality risks in heart and lung transplant recipients, particularly for non-Hodgkin's lymphoma.

This meta-analysis synthesizes data from multi-centre cohort and registry-based studies to evaluate cancer-related mortality among adult solid organ transplant recipients compared to the general population. The analysis reports a pooled standardized mortality ratio (SMR) of 2.21 (95% CI: 1.82-2.68) for cancer-related mortality in this population.

Specific findings indicate increased risk for certain organs and cancers. Mortality after heart transplantation showed an MRR of 2.08 (95% CI: 1.28-3.41), while lung transplantation showed an MRR of 1.83 (95% CI: 1.09-3.06; p=0.025). Furthermore, mortality from non-Hodgkin's lymphoma was reported as a fivefold increase. Conversely, no excess mortality risk was identified for prostate cancer.

The authors note significant between-study heterogeneity as a primary limitation of the findings. These results suggest that while certain transplant types are associated with higher cancer-related mortality risks, specific cancers like prostate cancer do not show an increased risk profile in this cohort. Clinical application is limited by the observed heterogeneity and the lack of reported follow-up durations.

How this fits prior evidence

This meta-analysis addresses a gap in understanding how solid organ transplantation impacts long-term cancer outcomes. While previous coverage has discussed various oncology comorbidities and mechanisms, such as the impact of fibromyalgia on symptom burden or the role of protein lactylation in tumor malignancy, this study specifically quantifies the increased risk of cancer-related mortality (SMR 2.21) following heart and lung transplants.

Living with an organ transplant is a major milestone, but it comes with unique health challenges. New data shows that people who receive solid organs, such as hearts or lungs, have a much higher risk of dying from certain cancers compared to the general population. Specifically, those with heart transplants saw more than double the risk of cancer-related death, while lung transplant recipients also faced a significantly higher risk.

The research highlights specific risks for different types of cancer. For example, people who received a heart or lung transplant showed a fivefold increase in mortality from non-Hodgkin's lymphoma. However, the data did not show any extra risk of death from prostate cancer for these patients.

While these findings are important for understanding long-term health after surgery, the study noted significant differences between the various studies included in the analysis. Because of this variation, the results should be viewed as a way to identify specific risks rather than a perfect prediction for every individual.

What this means for you:
Heart and lung transplant recipients face higher cancer mortality, especially from non-Hodgkin's lymphoma.

Common questions

Which organ transplants are linked to higher cancer risk?

The study found that people who received heart or lung transplants had a significantly higher risk of dying from cancer. Specifically, the mortality rate for cancer was more than double for heart transplant recipients and nearly double for those who received lung transplants.

Are there specific types of cancer that are more common after transplant?

Yes, the data showed a fivefold increase in deaths from non-Hodgkin's lymphoma among transplant recipients. In contrast, the study found no extra risk of death from prostate cancer for these patients.

How certain are these findings about cancer and transplants?

The results show a clear link between solid organ transplants and higher cancer-related deaths. However, because there was significant variation between the different studies analyzed, these figures represent an association rather than a guaranteed outcome for every patient.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
Organ transplantation is associated with an increased risk of cancer-related mortality; however, estimates from international cohorts vary widely. The aim of this systematic review and meta-analysis is to quantify this risk. We searched MEDLINE and OVID Embase and the Cochrane Central Register of Controlled Trials (CENTRAL) for population-based cohort studies reporting cancer-related mortality in adult solid organ transplant recipients up to 2nd October 2024. Meta-analysis was conducted using a restricted maximum likelihood random-effects model. Risk of bias was assessed using the Newcastle–Ottawa Scale. Seventeen registry-based studies and multicentre cohort studies met inclusion criteria. The pooled standardised mortality ratio for cancer mortality was 2.21 (95% CI: 1.82–2.68). Meta-regression showed higher mortality after heart [mortality rate ratio (MRR) 2.08, 95% CI: 1.28–3.41] and lung (MRR: 1.83, 95% CI: 1.09–3.06; p = 0.025) transplantation compared with kidney transplantation. Geographic variation was observed, with lower mortality in East Asia. This meta-analysis demonstrates that solid organ transplantation is associated with an increased in overall cancer-related mortality compared with the general population, with variation by organ type and cancer site. Prostate cancer showed no excess mortality risk, supporting current guidance against additional screening. In contrast, mortality from non-Hodgkin's lymphoma was increased fivefold, consistent with the established link between immunosuppression and post-transplant lymphoproliferative disease. Notably, geographic variation was observed, with lower mortality in East Asia, likely reflecting differences lifestyle risk factors and health care structures. However significant between study heterogeneity exists, underscoring the need for tailored prevention strategies, rather than relying on aggregated global estimates in this high-risk population. https://www.crd.york.ac.uk/PROSPERO/view/CRD42024617474, identifier CRD42024617474.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.